Key result
MetALD is linked to ~56% higher adverse liver outcomes than MASLD, with similar MACE.
Why the study?
Do MetALD and ALD increase the risk of adverse liver outcomes, MACE, and all-cause mortality compared to MASLD in adults with imaging-confirmed hepatic steatosis?
Population
341,601 adults with imaging-confirmed hepatic steatosis receiving outpatient care within the national…
Comparison
MetALD or ALD vs MASLD
Design
Cohort
Follow-up
median 5.5 years (IQR 3.0-8.4)
Authors
Loading...
In patients with steatotic liver disease, those with MetALD and ALD face higher risks of adverse liver outcomes and mortality compared to MASLD, though cardiovascular risk (MACE) remains similar across subtypes.
Cohort (n=341,601)
Yes
Do MetALD and ALD increase the risk of adverse liver outcomes, MACE, and all-cause mortality compared to MASLD in adults with imaging-confirmed hepatic steatosis?
Hazard Ratio: 1.56 (95% CI 1.5–1.62)
Absolute Event Rate: 1.12% vs 0.61%
In patients with steatotic liver disease, those with MetALD and ALD face higher risks of adverse liver outcomes and mortality compared to MASLD, though cardiovascular risk (MACE) remains similar across subtypes.
Ochoa‐Allemant et al. (2025) conducted a cohort in Steatotic liver disease (n=341,601). MetALD vs. MASLD was evaluated on incidence of adverse liver outcomes (cirrhosis, decompensation, hepatocellular carcinoma, liver transplant, liver-related death) (HR 1.56, 95% CI 1.50-1.62). Compared with MASLD, MetALD and ALD were associated with higher incidences of adverse liver outcomes (HR 1.56 and HR 2.33, respectively) and all-cause mortality, but similar incidences of MACE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: